aTyr Pharma, Inc. ATYR
aTyr Pharma, Inc. (Nasdaq: ATYR) is an immunology/inflammation drug developer. Its lead program, ATYR0101, is in Pre-clinical for fibrotic diseases (pulmonary fibrosis, systemic sclerosis, liver fibrosis, kidney fibrosis). Its next catalyst on record is efzofitimod (pulmonary sarcoidosis): Study-related activities for Proposed Phase 3 Study (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: efzofitimod (pulmonary sarcoidosis) — Study-related activities for Proposed Phase 3 Study (Q4 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| efzofitimod | pulmonary sarcoidosis with restrictive lung disease | protein/peptide | Phase 3 |
| efzofitimod | systemic sclerosis-associated interstitial lung disease (SSc-ILD) | protein/peptide | Phase 2 |
| ATYR0101 | fibrotic diseases | protein/peptide | Pre-clinical |
| ATYR2810 | oncology (solid tumors including osteosarcoma, NSCLC, TNBC, RCC, glioblastoma) | antibody | Pre-clinical |
Recent results and decisions
- Nov 5, 2026accepted aTyr reached alignment with FDA on protocol for Phase 3 study of efzofitimod in pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint.
Reached alignment with the FDA on the protocol for a global Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease.
Filing - Nov 5, 2026started aTyr initiated study-related activities for Phase 3 trial of efzofitimod in pulmonary sarcoidosis with restrictive lung disease.
The Company recently initiated study-related activities for the trial and is prioritizing strategic partnerships and/or licensing arrangements in order to advance the Phase 3 study beyond the completion of the initial study-related activities.
Filing - Nov 5, 2026n/a aTyr published Phase 3 EFZO-FIT results for efzofitimod in pulmonary sarcoidosis in The Lancet Respiratory Medicine.
Published the results of the Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis in The Lancet Respiratory Medicine.
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.